## Identification of hyper-methylated tumor suppressor genes-based diagnostic panel for esophageal squamous cell carcinoma (ESCC) in a Chinese Han population

Chenji Wang1†, Weilin Pu2†, Dunmei Zhao1, Yinghui Zhou1, Shuai Jiang2, Ting Lu1, Sidi Chen3, Zhenglei He1, Xulong Feng1, Ying Wang4, Caihua Li4, Shilin Li2, Li Jin2, Shicheng Guo5\*, Jiucun Wang2\*, Minghua Wang1\*

1 Department of Biochemistry and Molecular Biology, Medical College, Soochow University, Suzhou, Jiangsu, China

2State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China

3Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China

4Genesky Biotechnologies Inc., Shanghai, China

5Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield, WI, USA

**Running title:** A panel of DNA methylation biomarkers for ESCC diagnosis

Chenji Wang† and Weilin Pu† contributed equally on this work

**Corresponding authors:**

Minghua Wang, Ph.D, Department of Biochemistry and Molecular Biology, Medical College, Soochow University, Suzhou, Jiangsu, China, Phone: +86-0512-65880108, Fax: +86-0512-65880103, Email: mhwang@suda.edu.cn

Jiucun Wang, Ph.D, School of Life Sciences, Fudan University, Shanghai 200438, China, Phone: +86-021-51630606, Fax: +86-21-51630607, E-mail: [jcwang@fudan.edu.cn](mailto:jcwang@fudan.edu.cn).

Shicheng Guo, Ph.D. Center for Precision Medicine Research, Marshfield Clinic Research Institute, 1000 N Oak Ave, Marshfield, Wisconsin (WI) 54449 Telephone: 715-221-6443, Email: [Guo.Shicheng@marshfieldresearch.org](mailto:Guo.Shicheng@marshfieldresearch.org)

## Abstract

DNA methylation-based biomarkers were suggested to be promising for early cancer diagnosis. However, DNA methylation-based biomarkers for esophageal squamous cell carcinoma (ESCC), especially in Chinese Han populations have not been identified and evaluated quantitatively. Candidate tumor suppressor genes (N=65) were selected through literature searching and four public high-throughput DNA methylation microarray datasets including 136 samples totally were collected for initial confirmation. Targeted bisulfite sequencing was applied in an independent cohort of 94 pairs of ESCC and normal tissues from a Chinese Han population for eventual validation. We applied nine different classification algorithms for the prediction to evaluate to the prediction performance. *ADHFE1, EOMES, SALL1* and *TFPI2* were identified and validated in the ESCC samples from a Chinese Han population. All four candidate regions were validated to be significantly hyper-methylated in ESCC samples through Wilcoxon rank-sum test (*ADHFE1*, P = 1.7×10-3; *EOMES*, P = 2.9×10-9; *SALL1*, P = 3.9×10-7; *TFPI2*, p = 3.4×10-6). Logistic regression based prediction model shown a moderately ESCC classification performance (Sensitivity = 66%, Specificity = 87%, AUC = 0.81). Moreover, advanced classification method had better performances (random forest and naive Bayes). Interestingly, the diagnostic performance could be improved in non-alcohol use subgroup (AUC = 0.84). In conclusion, our data demonstrate the methylation panel of *ADHFE1*, *EOMES*, *SALL1* and *TFPI2* could be an effective methylation-based diagnostic assay for ESCC.

**Keywords: Esophageal squamous cell carcinoma (ESCC), DNA methylation, Biomarker, Diagnosis, Targeted bisulfite sequencing (TGS)**

**Background**

Esophageal cancer is one of the most aggressive malignant tumors with high prevalence and poor prognosis worldwide [1]. Esophageal cancer usually occurs as two subtypes, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), which differed significantly in pathogenesis, pathology, epidemiology and geographical distribution [2]. The regions of the highest occurrence of esophageal cancer stretching from northern China to northwestern Iran, including Japan and India, are localized in the so-called Asian Esophageal Cancer Belt [3; 4]. The prevalence of ESCC and EAC in these regions are significantly unbalanced with 90% of esophageal cancer patients are ESCCs [5]. In addition, the clinical outcomes of ESCC patients depend largely on its diagnosed stage [2]. The majority of ESCCs are diagnosed at advanced stages and the overall 5-year survival rate is relatively poor, while the 5-year survival rate for early-stage diagnosed ESCC patients is significantly higher [6]. Therefore, it is imperative to identify biomarkers for early diagnosis of ESCC patients.

DNA methylation, which usually occurs in CpG dinucleotides, functioning as an epigenetic modification in mammalian genome and is involved in regulating gene and microRNA expression and alternative splicing. Global hypo-methylation as well as the hyper-methylation of CpG islands in the tumor suppressor genes have been widely identified in the process of tumorigenesis [7]. DNA methylation was the first epigenetic alteration to be identified in cancer and multiple lines of studies have found that DNA methylation alterations could serve as biomarkers for cancer diagnosis including ESCC. For example, dozens of genes have been reported to be hyper-methylated in ESCC, including *APC, MGMT, CDH1, RASSF1* [8; 9; 10; 11]. In addition, due to the heterogeneity of ESCC, a single biomarker could only achieve relatively limited prediction ability, which calling for the comprehensive combinations of these candidate biomarkers.

In the present study, we first collected 65 candidate tumor suppressor genes and evaluated their methylation status in ESCC and adjacent control tissues from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. After a stringent biomarker selection procedure, four of the candidate hyper-methylated genes (*ADHFE1, EOMES, SALL1, TFPI2*) were validated with high-throughput datasets from public databases. Moreover, the methylation profiles of these four genes were further validated with targeted bisulfite sequencing method in 94 pairs of ESCC tumor and adjacent control tissues from a Chinese Han population, yielding a robust performance for ESCC diagnosis.

## Materials and Methods

### Biomarker selection based on publications and public datasets

Firstly, Candidate tumor suppressor genes were collected through the keyword matching (“tumor suppressor gene”) with custom script among 91,225 abstract downloaded from Pubmed database and manually re-checked (listed in Supplementary Table 1). In order to test the methylation status of these 65 candidate genes in ESCC patients, we searched high-throughput microarray datasets in TCGA and GEO database to collect the DNA methylation profiles of the ESCC samples. After stringent quality control, we found that TCGA project has quantified the methylation profiles of 84 ESCC and 3 normal tissues, as well as 78 EAC and 13 normal tissues. Due to the similarities which were shown through PCA analysis between adjacent control tissues from ESCC and EAC, the 13 normal tissues of EAC were included in our combined dataset as controls equally (Supplementary Figure 1). In addition, three datasets in GEO database named GSE52826, GSE74693 and GSE79366 were also retrieved, including 26 ESCC and 10 normal tissues. Eventually, 110 ESCC and 26 normal tissues were included from TCGA/GEO for further study. ComBat was applied for removing the batch effect between the different datasets [12]. Due to the fact that we want to obtain the diagnostic biomarkers which might be applied for liquid biopsy, we then defined the CpG sites with high methylation percent (>0.25) in the ESCCs and relatively lower methylation percent (< 0.25) in the adjacent control tissues as the significant CpG sites. Further, it is widely acknowledged that the methylation status of CpG sites was largely variable in different cell types. As a result, we then filtered out the significant CpG sites with high methylation percentage (> 0.15) in either peripheral blood mononuclear cells (PBMC, N = 111) or peripheral blood leucocytes (PBL, N = 527) of the healthy normal samples from the GEO database. The PBMC dataset came from the GSE53045 dataset, and the PBL dataset was the combination of GSE36054 and GSE42861 dataset [13; 14; 15]. Moreover, we selected the candidate genes with at least two eligible significant CpG sites for further validation. In summary, six genes were included (*ADHFE1, EOMES, RUNX1, SALL1, TFPI2, WT1,* Supplementary Table 2). After that, we designed the primers for these six genes separately and then applied for multiplex PCR system. Due to the GC percent, PolyT and the number of SNPs in the primers of our targeted regions, we only obtained the multiplex PCR system consisting of the four genes including *ADHFE1*, *EOMES*, *SALL1*, *TFPI2* but could not generate enough high quality reads for *RUNX1* and *WT1*. Therefore, these two genes were then discarded for further analysis. Finally, we validated the methylation of these four candidate genes with 94 pairs of Chinese ESCC and control samples (Table 1).

### Patients and samples

ESCC samples and their paired adjacent control tissues were obtained for validation study from the First Affiliated Hospital of Soochow University and Fourth Military Medical University between the years of 2011 and 2015. All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. The studies were approved by the institutional review boards of Soochow University at Jiangsu Province and Fudan University, Shanghai, China. Written informed consent was obtained from each study subject. In addition, all of the subjects were re-examined and confirmed by professional pathologists for histopathological diagnosis. All tissues were immediately frozen at -80oC after surgical resection. Face-to-face interviews were conducted by professional investigators with a comprehensive questionnaire, including clinical information on tobacco smoking, alcohol consumption and family history.

### DNA extraction, bisulfite conversion and targeted bisulfite sequencing

Genomic DNA from ESCC tumor tissue and adjacent control tissue samples were extracted by AllPrep DNA/RNA Mini Kit (Qiagen, Duesseldorf, Germany) according to the manufacturer’s protocols. For methylation analysis, 500 ng genomic DNA was subjected to bisulfite conversion using the EpiTect Fast DNA Bisulfite Kit (Qiagen, Duesseldorf, Germany). A multiplex PCR was performed first with optimized primer sets combination (Supplementary Table 3). PCR amplicons were diluted and amplified using indexed primers and the products (170bp – 270 bp) were separated by agarose electrophoresis and purified by QIAquick Gel Extraction kit (Qiagen, Duesseldorf, Germany). Libraries from different samples were quantified and pooled together equally, sequenced with the Illumina Hiseq 2000 platform according to the manufacturer's protocols. BSseeker2 software was utilized for reads mapping and methylation calling [16]. Samples and CpG sites with high missing rates (> 30%) were removed. In order to make sure the reliability of the technique and analysis pipeline, we take LINE-1 as the technical control, whose methylation rate was decreased in cancer tissues compared with normal tissues. Therefore, LINE-1 methylation status was applied to check the credibility of the experiments. Meanwhile, the conversion ratio of C to T in non-CpG sites were applied to evaluate the bisulfite conversion efficiency.

### The 5-aza-2’-deoxycytidine treatment and quantitative-PCR

### CaEs-17 cells lines were split to low density (25% confluence) per well into 6-well cell culture plates and incubated at 37°C in a humidified incubator with 5% CO2, following culturing overnight. Cells were treated with 5-aza-2′-deoxycytidine (DAC, Sigma, St. Louis, MO) at a concentration of 20 μM in the growth medium, which was exchanged every 24 h for a total of 96 h treatment. After treatment, total RNA was extracted using TRIzol reagent (ThermoFisher, Rockford, USA) from cultured cells. Reverse transcription was performed using 1.5 µg total RNA with an All-in-One cDNA Synthesis SuperMix (Bimake, Houston, TX, USA) according to the manufacturer's protocol. Meanwhile, qPCR was used to detect the expression of SALL1, EOMES, TFPI2, ADHFE1 mRNA in a reaction volume of 10 µl, including 5 µl SYBR Green (Bimake, Houston, TX, USA), 1 µl cDNA, 0.5 µl of each primer and 3 µl water. The mixture was incubated by the following program: 95°C for 5mins, 40 cycles of 95 °C for 15 secs, 60°C for 1min. The primers used for reverse transcription was listed in Supplementary Table 4.

### Statistical analysis and machine learning

In the first and second stage, we tested the differential methylation of the CpG sites between cancer and normal tissues using Wilcoxon rank-sum test. False discovery rate (FDR) correction was conducted for multiple test correction. In order to discriminate the ESCC tumor and normal tissues, we utilized several machine learning methods, including logistic regression (Package stats), support vector machine (SVM, Package e1071), random forest (Package randomForest), naïve Bayes (Package e1071), neural network (Package nnet), linear discriminant analysis (LDA, Package mda), mixture discriminant analysis (MDA, Package mda), as well as the flexible discriminant analysis (FDA, Package mda) followed with five-fold cross-validation. All statistical analyses were conducted using R 3.2.1 [17].

### Results

### Public datasets collection and CpG sites validation

In order to quantify the methylation status of these four candidate genes, public DNA methylation microarray datasets of ESCC were carefully searched. The detailed biomarker identification procedure was shown in Figure 1. In total, 110 ESCC tumor tissues and 26 adjacent control tissues were enrolled [18; 19; 20]. Based on the CpG sites selection criteria which was described in Patients and Methods, six significant CpG sites (cg20295442, cg20912169, cg22383888, cg04550052, cg04698114, cg12973591) located at the four candidate genes were selected for validation (Table 1).Integratively, though some of the six CpG sites did not reach the statistical significance threshold due to the limited sample size, we still believed that all of these 6 CpG sites may be of potential as the non-invasive potential biomarkers for ESCC and thus were included for validation. To test the prediction ability based on these six CpG sites, we built a prediction model based on the logistic regression using the methylation status of these 6 CpG sites without adjustment for age, gender and other covariates, which provided a fair good performance to discriminate between ESCC and normal tissues (Sensitivity = 79%, Specificity = 92%, AUC = 0.87). To further evaluate and validate the diagnostic ability of these six CpG sites, we then conducted the validation study in 94 paired ESCC and adjacent control tissue samples obtained from the patients from the Chinese Han population.

### Methylation status validation with targeted bisulfite sequencing

The characteristics of the ESCC patients are shown in Supplementary Table 5 In order to give a robust characterization of the methylation status of these 6 CpG sites as well as the four genes, we applied the targeted bisulfite sequencing method, which was based on the next generation sequencing (NGS) platforms. Because the NGS platforms could generate millions of reads with length > 200 bp, we then designed to test four genomic regions for the four candidate tumor suppressor genes for validation (Table 2). In the quality control process, we found that the bisulfite conversion rate (C to T ratio in non-CpG loci) of our samples were higher than 98%, and no significant difference was found between the tumor and adjacent control tissues (Figure 2A). Besides, we used the LINE-1 methylation status as technical control and showed that our study was robust and reliable (Figure 2B). In addition, the samples and the CpG sites with high missing rates were also filtered out as described in Patients and Methods. After quality control, 163 samples remained for further study. PCA analysis revealed that a significant distinction between ESCC samples and control samples (Supplementary Figure 2). Differential methylation analyses were conducted for the four genomic regions, suggesting a major difference between the ESCC and adjacent control tissues. A logistic regression model was then applied, and showed significant hyper-methylation status of the six selected CpG sites in the ESCC tissues (Table 1, cg20295442, p= 5.10×10-3; cg20912169, p= 2.10×10-3; cg22383888, p= 3.30×10-9; cg04550052, p= 2.50×10-4; cg04698114, p= 1.10×10-6; cg12973591, p = 3.30×10-5). To better characterize the methylation status of the four genomic regions as well as the four candidate genes, we averaged the methylation status of all the CpG sites in each genomic region and conducted the DMR analysis with the same approach. We found all these 4 genes are significantly differentially methylated between ESCC and normal samples (Figure 3). Based on the mean methylation status of the four genomic regions, the prediction ability of each region separately was evaluated through logistic regression without adjustment for age, gender and other covariates. The sensitivity of each region ranges from 29% to 69%, while the specificity ranges from 77% to 94%, and the AUC ranges from 0.64 to 0.78 (Table 2). Of these four candidates, *EOMES* showed the highest sensitivity (0.69) and AUC (0.78), while the *ADHFE1* showed the best specificity (0.94). Moreover, in the logistic model taking all of the four regions as predictors, we obtained the sensitivity of 66% and specificity of 87%, as well as the AUC of 0.81 (Supplementary Figure 3).

### The prediction performance of the diagnosis panel in different classification models

Several machine learning methods, including logistic regression model, random forest, support vector machine (SVM), neural network (NN), Naïve Bayes (NB), linear discriminant analysis (LDA), mixture discriminant analysis (MDA), flexible discriminant analysis (FDA) and gradient boosting machine (GBM) following with five-fold cross validation were utilized for ESCC classification based on the targeted bisulfite sequencing regions (Table 3). It turned out that the GBM model achieved the highest classification accuracy among all machine learning methods in train stage, whose sensitivity, specificity and accuracy were 82.6%, 85.6% and 84.0%. The naive bayes model achieved the best specificity (91.6%) in the train stage. In the test stage, the random forest and naive bayes performed with the best sensitivity (72.8%) and specificity (91.0%), respectively. In addition, the linear discriminant analysis and flexible discriminant analysis model both achieved the best accuracy (73.5%).

## The diagnostic ability in the ESCC subgroups

Previous studies have found several risk factors for the incidence of ESCC, including age, gender, smoking status, and alcohol status [21; 22; 23]. In order to explore the effects of these risk factors on the ESCC diagnosis, we conducted the subgroup analyses. Similarly, the mean methylation percentage of each genomic region was utilized. To explore the diagnostic ability in the young/old samples, we first divided the samples according to the median age of our patients. No significant difference between the sensitivity, specificity and the AUC between the two subgroups (Supplementary Table 6). The AUCs in the two subgroups was 0.82 and 0.80 for the young and old subgroups, respectively (Supplementary Figure 4A-B). When it comes to the gender, the difference was still quite limited (AUC: 0.79 vs. 0.82 for male and female subgroups, Supplementary Table 7). Similarly, no significant difference of the diagnostic performances was found between smoker/non-smoker subgroup analysis (Supplementary Table 8). However, when concentrating on the effect of alcohol use, we found that the non-alcohol use subgroup showed obviously higher AUC than that of the alcohol use subgroup (0.84 vs. 0.77 respectively, Supplementary Table 9). The significant difference in the diagnostic performance between the alcohol use and non-alcohol use subgroup indicates that alcohol use may contribute to the epigenetic changes in ESCC as well as to the pathogenesis of ESCC.

## The association between gene expression and methylation of the candidate genes

It is widely accepted that the gene methylation could regulate the gene expression level and further affect the phsiological activities. To assess the associations between gene expression and methylation of these four candidates, we conducted the study to demethylase the human esophageal squamous carcinoma cell line (CaES-17) with 5-aza-2’-deoxycytidine and quantified the gene expression of these candidate genes. We found three of these four genes (*EOMES, SALL1 and TFPI2*) shown a significant up-regulation after 5-aza-2’-deoxycytidine treatment, while *ADHFE1* showed a slight up-regulation yet the statistic test was not quite significant (Figure 4). In summary, our results validated the inverse correlations between gene expression and methylation of these four genes, and suggesting that abnormal methylation change of these genes might be involved in ESCC carcinogenesis mediated by gene expression change.

## Discussion

In this study, 4 out of 65 candidate tumor suppressor genes (*ADHFE1, EOMES, SALL1, TFPI2*) were found to be hyper-methylated in ESCC tissues while hypo-methylated in the adjacent control tissues as well as the peripheral blood samples, and were further validated in an independent 94 pairs of ESCC and adjacent control tissues from Chinese Han population.

Of these four candidate genes, alcohol dehydrogenase, iron containing 1 (*ADHFE1*) encodes hydroxyacid-oxoacid transhydrogenase, which is responsible for the oxidation of 4-hydroxybutyrate in mammalian tissues [24]. *ADHFE1* promoter hyper-methylation was found in [colorectal cancer](https://www.ncbi.nlm.nih.gov/pubmed/24886599/) (CRC) and the alcohol could down-regulate the expression of *ADHFE1* through hyper-methylation and further induce the proliferation of CRC cells [25; 26]. Meanwhile, Xi et al. also identified that *ADHFE1* was one of the target genes of differentially expressed miRNAs in esophageal adenocarcinomas [27].

*EOMES* belongs to the TBR1 (T-box brain protein 1) sub-family of T-box genes, encoding a transcription factor which is necessary for the embryonic development. It has been reported that *EOMES* promoter methylation could serve as a promising biomarker for the prediction of occurrence, recurrence and prognosis of bladder cancer [28; 29; 30]. In addition, EOMES has also been confirmed to have potential anti-cancer functions through siRNA experiments, and was regarded as a candidate tumor suppressor gene for human hepatocellular carcinoma [31]. Spalt like transcription factor 1(*SALL1*) encodes a zinc finger transcriptional repressor, which has recently been identified as a tumor suppressor gene, whose expression was in positive correlation with *CDH1* and associated with the survival of patients in breast cancer [32]. In addition, *SALL1* hyper-methylation has already been confirmed as the diagnostic biomarker for breast cancer and other epithelial cancers, especially for the colorectal cancer [33].

Tissue factor pathway inhibitor 2 (*TFPI2*) encodes a member of the Kunitz-type serine proteinase inhibitor family, and was found to be down-regulated in 75% of esophageal carcinomas and in most esophageal carcinoma cell lines [34]. Moreover, Yan Jia et al. have found that the *TFPI2* is frequently methylated in esophageal cancer with a progression tendency, and the restoration of *TFPI2* expression could inhibit the invasion, migration, colony formation and proliferation in KYSE70 cell line [35]. Therefore, multiple studies have incorporated *TFPI2* into the DNA methylation-based disgnostic panel for ESCC early diagnosis [36; 37]. Similarly, Hamza Chettouh et al. also showed that the methylation status of *TFPI2* promoter could detect Barrett’s oesophagus when applied to Cytosponge samples [38]. Moreover, Liu et al. also revealed that celecoxib, which was reported to induce promoter demethylation and reactivate expression of some metastasis-suppressor genes in lung cancer cells, could demethylate the methylation status of *TFPI2* in vivo and up-regulate the gene expression as well as inducing the apoptosis of cancer cells [39]. Therefore, the DNA methylation status of *TFPI2* may also be implicated in ESCC treatment.

The accurate early diagnosis of cancer is a great challenge due to the cancer heterogeneity. In our study, we selected four candidate tumorigenesis genes and applied the targeted bisulfite sequencing method to explore the methylation status of our candidate CpG sites as well as their adjacent genomic regions, thus yielding a robust estimation of the methylation status of the candidate genes. With the fast development of NGS technology, the targeted bisulfite sequencing method is becoming more and more popular for methylation detection because of high accuracy, high-throughput and cost-effective. In the past studies, we found the single DNA methylation biomarker usually cannot provide enough prediction power in cancer diagnosis. According to our results, the panel consisting of these four candidate genes could distinguish the ESCC tumors with higher specificity and sensitivity compared with single biomarker.

In summary, a panel with four genes was identified and achieved a fair good accuracy in classifying ESCC from normal tissues. However, according to diagnosis performance, our prediction model still has more space to be improved when we introduce more biomarkers. Multi-omics datasets, including genomics, epigenomics and proteomics, which could provide biomarkers in different biological layers, could contribute to the accurate non-invasive diagnosis of esophageal squamous cell carcinoma in the future. In addition, the diagnostic ability of our panel was only validated in ESCC samples but not in EAC samples due to our limited samples, and further studies based on EAC samples should be conducted.

## Conclusion

Integrated analysis of public literatures and multiples high-throughput DNA methylation microarray datasets were conducted and discovered four tumor suppressor genes (*ADHFE1, EOMES, SALL1, TFPI2*) as the candidate biomarkers for ESCC diagnosis. All four tumor suppressor genes were then successfully validated in an independent cohort including 94 pairs of ESCC and adjacent control tissues. Moreover, the EOMES showed the highest sensitivity (0.69) and AUC (0.78), while the ADHFE1 showed the best specificity (0.94). Methylation profiles of *ADHFE1, EOMES, SALL1, TFPI2* could be an effective methylation-based assay (Sensitivity = 0.66, Specificity = 0.87, AUC = 0.81) for the ESCC diagnosis with high specificity.

## Acknowledgements

We thank all participating subjects for their kind cooperation in this study.

## Funding

The study was supported by research grants from the National Natural Science Foundation of China (81572923, 31521003, 81071957), the Jiangsu Province Postdoctoral Research Funding (7131708615), the Key Project in the National Science & Technology Pillar Program (2011BAI09B00), a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Suzhou City Science and Technology Program (SYS 201419), and 111 Project (B13016).Computational support was provided by High-End Computing Center located at Fudan University.

## Availability of data and materials

The datasets used and analyzed in this study are available from the corresponding author on request.

## Consent for publication

Not applicable

## Competing interests

The authors declare that they have no competing interests.

## Authors’ contributions

Minghua Wang, Jiucun Wang, Li Jin, Yinghui Zhou and Shicheng Guo contributed to the conception and design of the study. Chenji Wang, Shuai Jiang, Dunmei Zhao, Zhenglei He and Xulong Feng contributed to the sample collection and DNA extraction, Ying Wang and Caihua Li conducted the targeted bisulfite sequencing experiments for the validation stage, Weilin Pu, Sidi Chen and Chenji Wang contributed to TCGA and GEO as well as the targeted bisulfite sequencing data analysis. Weilin Pu, Minghua Wang, Jiucun Wang and Shicheng Guo wrote the manuscript. All authors read and approved the final manuscript.

### Figure legends

### Figure 1. Flow diagram of the study design

Candidate tumor suppressor genes were selected based on literature screening, and their methylation status in ESCC and adjacent control tissues were tested with the ESCC methylation data from the TCGA/GEO datasets. Moreover, the PBMC and PBL methylation datasets from healthy controls from GEO database were also included for further confirmation. Finally, due to the limitations of the multiplex PCR design, four of the six candidate tumor suppressor genes were then selected and validated with targeted bisulfite sequencing in an independent Chinese Han ESCC patients.

### Figure 2. Quality control and the methylation status of these four candidate genomic regions.

Panels A represent the bisulfite conversion rate calculated by using the number of transformed C to T divided by the number of C of non-CpGs in each sample. Panel B represent the methylation status of the technical control LINE-1, which has been shown to be hypo-methylated in several different kinds of tumors. Panel C-F represents the CpG sites in regions covering *ADHFE1, EOMES, SALL1, TFPI2*, respectively. The x axis represents actual position of each CpG sites in the hg19 reference genome. The y axis represents the mean methylation percentage in the ESCC tumor tissues as well as the normal tissues for each of the CpG sites.

### Figure 3. The mean methylation status of each genomic region in tumor and normal tissues

Panels A-D represent the mean methylation status of the genomic regions covering *ADHFE1, EOMES, SALL1, TFPI2*, respectively. Each point represents mean methylation percentage in a genomic region of a sample. The boxplot showed the overall methylation percentage of different groups in each genomic region. P-value is calculated through the Wilcoxon rank-sum test and the Benjamini-Hochberg procedure was applied for multiple test correction.

### Figure 4. Gene expression change of candidate genes after the treatment of 5-aza-2’-deoxycytidine.

The expression profiles of these four genes before and after 5-Aza treatment in CaES-17 cell line was shown. The RNA quantification was conducted at three replicates for each gene and the GAPDH mRNA levels were used as an internal standard. The 2−ΔΔCq method was used to analyze the relative changes in these four genes. The Student’s t-test was carried out to test the differential expression after the 5-Aza treatment.

## Table legends

### Table 1. The methylation status of the 6 CpG sites in the TCGA dataset and the validation dataset

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **CpGsite** | **Gene** | **Position(hg19)** | **Relation to**  **CpG\_Island** | **McaMa** | **McoMa** | **P valueb** | **Sensc** | **Specc** | **AUCc** |
| TCGA | cg20295442 | *ADHFE1* | chr8:67344665 | Island | 0.26 | 0.15 | 0.18 | 0.42 | 0.85 | 0.61 |
| cg20912169 | *ADHFE1* | chr8:67344720 | Island | 0.26 | 0.14 | 0.22 | 0.46 | 0.85 | 0.60 |
| cg22383888 | *EOMES* | chr3:27764816 | N\_shore | 0.53 | 0.22 | **3.10×10-7** | 0.77 | 0.92 | 0.87 |
| cg04550052 | *SALL1* | chr16:51184355 | Island | 0.46 | 0.22 | **7.10×10-5** | 0.79 | 0.85 | 0.78 |
| cg04698114 | *SALL1* | chr16:51184379 | Island | 0.47 | 0.22 | **1.90×10-4** | 0.77 | 0.85 | 0.77 |
| cg12973591 | *TFPI2* | chr7:93519473 | Island | 0.33 | 0.15 | 0.06 | 0.63 | 0.88 | 0.65 |
|  |  |  |  |  |  |  |  |  |  |  |
| Validation | cg20295442 | *ADHFE1* | chr8:67344665 | Island | 0.18 | 0.09 | **5.10×10-3** | 0.28 | 0.95 | 0.63 |
| cg20912169 | *ADHFE1* | chr8:67344720 | Island | 0.17 | 0.07 | **2.10×10-3** | 0.30 | 0.94 | 0.64 |
| cg22383888 | *EOMES* | chr3:27764816 | N\_shore | 0.31 | 0.11 | **3.30×10-9** | 0.55 | 0.94 | 0.77 |
| cg04550052 | *SALL1* | chr16:51184355 | Island | 0.29 | 0.13 | **2.50×10-4** | 0.44 | 0.91 | 0.67 |
| cg04698114 | *SALL1* | chr16:51184379 | Island | 0.34 | 0.16 | **1.10×10-6** | 0.47 | 0.96 | 0.72 |
| cg12973591 | *TFPI2* | chr7:93519473 | Island | 0.25 | 0.08 | **3.30×10-5** | 0.49 | 0.89 | 0.69 |

aMcaM represents the mean methylation percentage of the cases, and the McoM represents the mean methylation percentage of the controls. bP value is calculated through the Wilcoxon rank-sum test followed by FDR (false discovery rate) adjustment for multiple correction. cSens = sensitivity, while Spec = specificity, AUC = area under curve. The sensitivity, specificity as well as the AUC were both with a logistic regression prediction model without adjustment for gender, age and smoking status and alcohol status.

### Table 2. The mean methylation status of the 4 genomic regions in the validation datasets

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Genomic**  **Regiona** | **No.**  **CpG sitesb** | **CpGsite**  **Included** | **Gene** | **McaMc** | **McoMc** | **P valued** | **log10(OR)e** | **95% CIe** | **Sensf** | **Specf** | **AUCf** |
| chr8:67344610-67344805 | 24 | cg20295442,  cg20912169 | *ADHFE1* | 0.24 | 0.15 | **1.70×10-3** | 2.20 | 1.00-3.72 | 0.29 | 0.94 | 0.64 |
| chr3:27764697-27764940 | 8 | cg22383888 | *EOMES* | 0.38 | 0.24 | **2.90×10-9** | 3.88 | 2.51-5.51 | 0.69 | 0.77 | 0.78 |
| chr16:51184268-51184468 | 18 | cg04550052,  cg04698114 | *SALL1* | 0.37 | 0.19 | **3.90×10-7** | 2.41 | 1.51-3.51 | 0.53 | 0.90 | 0.74 |
| chr7:93519367-93519503 | 13 | cg12973591 | *TFPI2* | 0.28 | 0.13 | **3.40×10-6** | 3.82 | 2.26-5.89 | 0.50 | 0.91 | 0.71 |

aGenomic region represents the genomic coverage of the reads with targeted bisulfite sequencing, and the genomic coordinates shown here is based on the hg19 version of the genome. bNo.CpG sites represents the number of the CpG sites in each region. cMcaM represents the mean methylation percentage of the cases in each region, which consisting of several CpG sites, while the McoM represents the mean methylation percentage of the controls in each region. dP value is calculated through the Wilcoxon rank-sum test following with FDR (false discovery rate) adjustment for multiple correction. e OR and 95% CI were conducted through logistic regression. fSens = sensitivity, while Spec = specificity, AUC = area under curve. The sensitivity, specificity as well as the AUC were both with a logistic regression prediction model without adjustment for gender, age and smoking status and alcohol status.

### Table 3. Diagnosis accuracy, sensitivity and specificity of different classification models with five-fold cross-validation

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Methods** | **Train** | | | **Test** | | |
| **Sensitivity** | **Specificity** | **Accuracy** | **Sensitivity** | **Specificity** | **Accuracy** |
| Logistic Regression | 0.683 | 0.873 | 0.773 | 0.645 | 0.830 | 0.732 |
| Random Forest | 0.726 | 0.739 | 0.732 | **0.728** | 0.741 | 0.734 |
| Supporting Vector Machine | 0.635 | 0.907 | 0.764 | 0.599 | 0.881 | 0.731 |
| Naive Bayes | 0.539 | **0.916** | 0.718 | 0.532 | **0.910** | 0.709 |
| Neural Network | 0.701 | 0.841 | 0.768 | 0.667 | 0.794 | 0.726 |
| Linear Discriminant Analysis | 0.617 | 0.906 | 0.754 | 0.594 | 0.894 | **0.735** |
| Mixture Discriminant Analysis | 0.618 | 0.868 | 0.736 | 0.564 | 0.843 | 0.695 |
| Flexible Discriminant Analysis | 0.616 | 0.907 | 0.754 | 0.594 | 0.894 | **0.735** |
| Gradient Boosting Machine | **0.826** | 0.856 | **0.840** | 0.699 | 0.728 | 0.713 |

The mean methylation percentage of each genomic region was considered as the independent variable for constructing the models, which means that all of the models were based on these five independent variables without adjustment for gender, age, smoking status and alcohol status. Sensitivity, specificity and classification accuracy were the mean value in fiv-efold cross-validations with 1,000 replications.

## Reference

[1] R.L. Siegel, K.D. Miller, and A. Jemal, Cancer statistics, 2016. CA: a cancer journal for clinicians 66 (2016) 7-30.

[2] P.C. Enzinger, and R.J. Mayer, Esophageal cancer. The New England journal of medicine 349 (2003) 2241-52.

[3] M.S. Khuroo, S.A. Zargar, R. Mahajan, and M.A. Banday, High incidence of oesophageal and gastric cancer in Kashmir in a population with special personal and dietary habits. Gut 33 (1992) 11-5.

[4] J. Kmet, and E. Mahboubi, Esophageal cancer in the Caspian littoral of Iran: initial studies. Science 175 (1972) 846-53.

[5] A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman, Global cancer statistics. CA Cancer J Clin 61 (2011) 69-90.

[6] S. Besharat, A. Jabbari, S. Semnani, A. Keshtkar, and J. Marjani, Inoperable esophageal cancer and outcome of palliative care. World J Gastroenterol 14 (2008) 3725-8.

[7] S.B. Baylin, M. Esteller, M.R. Rountree, K.E. Bachman, K. Schuebel, and J.G. Herman, Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10 (2001) 687-92.

[8] K. Kawakami, J. Brabender, R.V. Lord, S. Groshen, B.D. Greenwald, M.J. Krasna, J. Yin, A.S. Fleisher, J.M. Abraham, D.G. Beer, D. Sidransky, H.T. Huss, T.R. Demeester, C. Eads, P.W. Laird, D.H. Ilson, D.P. Kelsen, D. Harpole, M.B. Moore, K.D. Danenberg, P.V. Danenberg, and S.J. Meltzer, Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 92 (2000) 1805-11.

[9] J. Chen, Z.J. Huang, Y.Q. Duan, X.R. Xiao, J.Q. Jiang, and R. Zhang, Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism and folate intake in esophageal squamous cell carcinoma. Asian Pac J Cancer Prev 13 (2012) 5303-6.

[10] S. Takeno, T. Noguchi, S. Fumoto, Y. Kimura, T. Shibata, and K. Kawahara, E-cadherin expression in patients with esophageal squamous cell carcinoma: promoter hypermethylation, Snail overexpression, and clinicopathologic implications. Am J Clin Pathol 122 (2004) 78-84.

[11] T. Kuroki, F. Trapasso, S. Yendamuri, A. Matsuyama, H. Alder, M. Mori, and C.M. Croce, Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 63 (2003) 3724-8.

[12] J.T. Leek, W.E. Johnson, H.S. Parker, A.E. Jaffe, and J.D. Storey, The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28 (2012) 882-883.

[13] M.V. Dogan, B. Shields, C. Cutrona, L. Gao, F.X. Gibbons, R. Simons, M. Monick, G.H. Brody, K. Tan, S.R. Beach, and R.A. Philibert, The effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American women. BMC Genomics 15 (2014) 151.

[14] R.S. Alisch, B.G. Barwick, P. Chopra, L.K. Myrick, G.A. Satten, K.N. Conneely, and S.T. Warren, Age-associated DNA methylation in pediatric populations. Genome Res 22 (2012) 623-32.

[15] Y. Liu, M.J. Aryee, L. Padyukov, M.D. Fallin, E. Hesselberg, A. Runarsson, L. Reinius, N. Acevedo, M. Taub, M. Ronninger, K. Shchetynsky, A. Scheynius, J. Kere, L. Alfredsson, L. Klareskog, T.J. Ekstrom, and A.P. Feinberg, Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol 31 (2013) 142-7.

[16] W. Guo, P. Fiziev, W. Yan, S. Cokus, X. Sun, M.Q. Zhang, P.-Y. Chen, and M. Pellegrini, BS-Seeker2: a versatile aligning pipeline for bisulfite sequencing data. BMC genomics 14 (2013) 774.

[17] R.B. Dessau, and C.B. Pipper, [''R"--project for statistical computing]. Ugeskr Laeger 170 (2008) 328-30.

[18] X.F. Li, F.Y. Zhou, C.Y. Jiang, Y.N. Wang, Y.Q. Lu, F. Yang, N.C. Wang, H.J. Yang, Y.F. Zheng, and J.R. Zhang, Identification of a DNA Methylome Profile of Esophageal Squamous Cell Carcinoma and Potential Plasma Epigenetic Biomarkers for Early Diagnosis. PloS one 9 (2014).

[19] T. Kishino, T. Niwa, S. Yamashita, T. Takahashi, H. Nakazato, T. Nakajima, H. Igaki, Y. Tachimori, Y. Suzuki, and T. Ushijima, Integrated analysis of DNA methylation and mutations in esophageal squamous cell carcinoma. Mol Carcinog 55 (2016) 2077-2088.

[20] J.J. Hao, D.C. Lin, H.Q. Dinh, A. Mayakonda, Y.Y. Jiang, C. Chang, Y. Jiang, C.C. Lu, Z.Z. Shi, X. Xu, Y. Zhang, Y. Cai, J.W. Wang, Q.M. Zhan, W.Q. Wei, B.P. Berman, M.R. Wang, and H.P. Koeffler, Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nature genetics 48 (2016) 1500-1507.

[21] Y. Toh, E. Oki, K. Ohgaki, Y. Sakamoto, S. Ito, A. Egashira, H. Saeki, Y. Kakeji, M. Morita, Y. Sakaguchi, T. Okamura, and Y. Maehara, Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol 15 (2010) 135-144.

[22] N. Pandeya, G. Williams, A.C. Green, P.M. Webb, D.C. Whiteman, and A.C. Study, Alcohol Consumption and the Risks of Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus. Gastroenterology 136 (2009) 1215-1224.

[23] J.M. Wang, B. Xu, J.Y. Rao, H.B. Shen, H.C. Xue, and Q.W. Jiang, Diet habits, alcohol drinking, tobacco smoking, green tea drinking, and the risk of carcinoma in the Chinese esophageal population squamous cell. Eur J Gastroen Hepat 19 (2007) 171-176.

[24] T. Kardon, G. Noel, D. Vertommen, and E.V. Schaftingen, Identification of the gene encoding hydroxyacid-oxoacid transhydrogenase, an enzyme that metabolizes 4-hydroxybutyrate. FEBS letters 580 (2006) 2347-50.

[25] J.W. Moon, S.K. Lee, Y.W. Lee, J.O. Lee, N. Kim, H.J. Lee, J.S. Seo, J. Kim, H.S. Kim, and S.H. Park, Alcohol induces cell proliferation via hypermethylation of ADHFE1 in colorectal cancer cells. Bmc Cancer 14 (2014).

[26] C.H. Tae, K.J. Ryu, S.H. Kim, H.C. Kim, H.K. Chun, B.H. Min, D.K. Chang, P.L. Rhee, J.J. Kim, J.C. Rhee, and Y.H. Kim, Alcohol dehydrogenase, iron containing, 1 promoter hypermethylation associated with colorectal cancer differentiation. BMC Cancer 13 (2013) 142.

[27] T. Xi, and G.Z. Zhang, Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. Pathol Res Pract 213 (2017) 83-88.

[28] T. Reinert, M. Borre, A. Christiansen, G.G. Hermann, T.F. Orntoft, and L. Dyrskjot, Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation. PloS one 7 (2012) e46297.

[29] T. Reinert, C. Modin, F.M. Castano, P. Lamy, T.K. Wojdacz, L.L. Hansen, C. Wiuf, M. Borre, L. Dyrskjot, and T.F. Orntoft, Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 17 (2011) 5582-92.

[30] Y.J. Kim, H.Y. Yoon, J.S. Kim, H.W. Kang, B.D. Min, S.K. Kim, Y.S. Ha, I.Y. Kim, K.H. Ryu, and S.C. Lee, HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array‐based DNA methylation and expression profiling. International journal of cancer 133 (2013) 1135-1142.

[31] F. Gao, Y. Xia, J. Wang, Z. Lin, Y. Ou, X. Liu, W. Liu, B. Zhou, H. Luo, B. Zhou, B. Wen, X. Zhang, and J. Huang, Integrated analyses of DNA methylation and hydroxymethylation reveal tumor suppressive roles of ECM1, ATF5, and EOMES in human hepatocellular carcinoma. Genome Biol 15 (2014) 533.

[32] J. Wolf, K. Muller-Decker, C. Flechtenmacher, F. Zhang, M. Shahmoradgoli, G.B. Mills, J.D. Hoheisel, and M. Boettcher, An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation. Oncogene 33 (2014) 4273-4278.

[33] V.K. Hill, L.B. Hesson, T. Dansranjavin, A. Dallol, I. Bieche, S. Vacher, S. Tommasi, T. Dobbins, D. Gentle, D. Euhus, C. Lewis, R. Dammann, R.L. Ward, J. Minna, E.R. Maher, G.P. Pfeifer, and F. Latif, Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer 9 (2010).

[34] Y.L. Ran, J. Pan, H. Hu, Z. Zhou, L.C. Sun, L. Peng, L. Yu, L.X. Sun, J. Liu, and Z.H. Yang, A Novel Role for Tissue Factor Pathway Inhibitor-2 in the Therapy of Human Esophageal Carcinoma. Hum Gene Ther 20 (2009) 41-49.

[35] Y. Jia, Y.S. Yang, M.V. Brock, B.P. Cao, Q.M. Zhan, Y.Z. Li, Y.Z. Yu, J.G. Herman, and M.Z. Guo, Methylation of TFPI-2 is an early event of esophageal carcinogenesis. Epigenomics 4 (2012) 135-146.

[36] S. Tsunoda, E. Smith, N.J. De Young, X. Wang, Z.Q. Tian, J.F. Liu, G.G. Jamieson, and P.A. Drew, Methylation of CLDN6, FBN2, RBP1, RBP4, TFP12, and TMEFF2 in esophageal squamous cell carcinoma. Oncol Rep 21 (2009) 1067-1073.

[37] S. Corrie, P. Sova, G. Lawrie, B. Battersby, N. Kiviat, and M. Trau, Development of a multiplexed bead-based assay for detection of DNA methylation in cancer-related genes. Mol Biosyst 5 (2009) 262-268.

[38] H. Chettouh, O. Mowforth, N. Galeano-Dalmau, N. Bezawada, C. Ross-Innes, S. MacRae, I. Debiram-Beecham, M. O'Donovan, and R.C. Fitzgerald, Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut (2017).

[39] J.F. Liu, Y.S. Li, P.A. Drew, and C. Zhang, The effect of celecoxib on DNA methylation of CDH13, TFPI2, and FSTL1 in squamous cell carcinoma of the esophagus in vivo. Anti-Cancer Drug 27 (2016) 848-853.